The company said the RMI (request for more information) response is a key step towards achieving the coveted manufacturing license for the 51,000-square-foot, fully automated facility
Agraflora Organics International Inc () (OCTMKTS:AGFAF) has submitted a formal response to Health Canada's first request for more information (RMI) regarding the standard processing licence application for Agraflora's 51,000-square-foot, fully automated edibles manufacturing facility in Winnipeg, Manitoba.
In a statement Friday, the company said the RMI response is a key step towards achieving the standard processing license for the edibles facility. Agraflora in May submitted its site evidence package to Health Canada for the manufacturing license.
AgraFlora noted that on August 27 it launched research and development trials through its Health Canada R&D license to dial in formulations for cannabis-activated pectin and gelatin gummies, hard candy, and sugar-free variants.
READ: AgraFlora says subsidiary Farmako in distribution agreement with Adjupharm to supply medical cannabis in Germany
The Vancouver-based company said it is currently in discussions with multiple Canadian cannabis companies with respect to product development and formulation as an R&D service. It believes that R&D services contracts are a critical path to long-term production relationships.
"Obtaining the Manufacturing License at the Edibles Facility is a major milestone for the company and today we completed an important step by submitting our RMI request,” said James Fletcher, co-founder and operational manager for Edibles and Infusions Corporation, a subsidiary that runs the plant.
“I believe we have submitted a strong application, and, with today's RMI clarifications, we are one step closer towards receiving the Manufacturing License and commencing commercial operations at the Edibles Facility.”
Agraflora’s strategy is two-pronged — supply the Canadian recreational market with high-potency flower and edible products, while serving the European medical cannabis market.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
